Simcere takes a stake in Boda Pharma
China-based Simcere Pharmaceutical Group announced that it will acquire a 51 percent stake in Boda Pharmaceutical. Simcere produces a neuroprotective stroke management medication, and Boda manufactures the only other injectable edaravone products in China. By taking a stake in Boda, Simcere will own the entire injectable edaravone market in the country.
- check out Simcere's release for more
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
